Drugs / Triptoreline

Trials 5 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/31 trial
Phase 2/3 NCT04242017 Jul 2020 → Feb 2026 overdue prostate cancer Universitaire Ziekenhuizen KU Leuven Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT05352178 Apr 2022 → Apr 2027 expected metastatic malignant neoplasm, metastatic prostate carcinoma Universitaire Ziekenhuizen KU Leuven Recruiting No outcome recorded
Phase 3 NCT01973816 Sep 2014 → Oct 2022 endometriosis University Hospital, Rouen Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00866008 Oct 2008 → Jan 2011 Bart CJM Fauser Terminated No outcome recorded
Phase not applicable1 trial
NCT03307720 Dec 2017 → Feb 2018 female infertility, ovarian disorder Ginegorama S.L. Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01353846 Comparator May 2011 → Nov 2012 infertility disorder Instituto Valenciano de Infertilidad, IVI VALENCIA Unknown No outcome recorded
Phase 4 NCT00633347 Comparator Jan 2007 → Oct 2009 infertility disorder Instituto Valenciano de Infertilidad, IVI VALENCIA Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Triptoreline “Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or...” NCT05352178
6

“administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval” NCT03307720

“Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg.” NCT01353846

Triptoreline (Decapeptyl)” NCT00866008

NCT04242017

NCT00633347

NCT01973816

Known as Triptoreline (Decapeptyl) Triptoreline (Decapeptyl)NCT00866008
Action Activate “GnRH agonist” NCT00633347
Route Intramuscular “administered in a single intramuscular injection (IM)” NCT00633347